PIC Therapeutics has raised $35m in a Series A funding round led by OrbiMed to develop therapies for drug-resistant breast cancer.

New investors Lumira Ventures and Harrington Discovery Institute also took part in the financing.

The funding round saw participation from current investors of the company, Advent Life Sciences and Belinda Termeer. This participation extended initial seed funding, which is crucial to meet key milestones.

The company will utilise the Series A funds to progress its small molecule drug presently in development into first-in-human clinical trials for advanced metastatic breast cancer.

This drug is an allosteric protein translation modulator that acts on eIF4E.

Additionally, the funding proceeds will be utilised to back the development of PIC’s pipeline of emerging cancer indications.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

PIC Therapeutics CEO Katherine Bowdish said: “This financing from a committed and distinguished investor syndicate, which includes new and existing investors, underscores the progress we’ve made to advance our lead programme toward our goal of cancer therapies that broadly address cancer-driving oncogenes via a fundamental mechanism in protein translational modulation.

“We are well positioned to build a leading mechanistic-based oncology company that brings promising science to cancer patients with drug-resistant tumours.”

The company is focusing on a fundamental mechanism at the intersection of several oncogenic signalling pathways that leads to the death of apoptotic cancer cells without impacting normal cells. 

Allosteric modulation of eIF4E provides various advantages to prior methods and targets several drivers of pharmacology at the same time. 

This approach permits the PIC’s small molecules to effectively cause differential CAP-dependent translation in target cells.

According to preclinical research, PIC compounds modulate protein translation but do not hinder the process.